🔗 Share this article

Given that the US undertakes unprecedented adjustments to its immunization guidelines, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Vaccine Program

Agency leaders planned to announce major revisions to the childhood vaccination calendar in December, aligning the US with Denmark’s national calendar, sources say – a major change that would put the US out of alignment with much of the world with insufficient data for improved outcomes. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A New Direction at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric shot schedules in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a population about the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent experience in medication creation, oversight or management, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Former directors of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

This division has an enormous workload at the FDA, she stated.

“The public just focuses on the new drug program, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one need to be supervised,” Woodcock said. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the job, which oversees over 5,000 employees. “It is a huge leadership role, if you do it right,” she added.

Response and Disputed Programs

Regarding questions about Dr. Høeg's qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions stem from flawed premises”.

“Her experience matches the duties of her role,” the spokesperson stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day drug-approval program that apparently concerned her predecessors. “By what process are these medications being picked for this voucher program? Who makes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of pharmaceuticals, except for vaccines.”

Established Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, track record, critics observe. She authored a research paper using unconfirmed volunteer-provided data to estimate the incidence of myocarditis following COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the current government included altering guidelines for new vaccines and ending “optional” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has allegedly suggested excluding adolescent males from obtaining Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to fit the evidence in a extremely misleading, dishonest way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|